Olga Bruyaka
Title
Cited by
Cited by
Year
Do science and money go together? The case of the French biotech industry
R Durand, O Bruyaka, V Mangematin
Strategic Management Journal 29 (12), 1281-1299, 2008
912008
Sell-off or shut-down? Alliance portfolio diversity and two types of high tech firms’ exit
O Bruyaka, R Durand
Strategic Organization 10 (1), 7-30, 2012
412012
Strategic corporate social responsibility and orphan drug development: Insights from the US and the EU biopharmaceutical industry
O Bruyaka, HK Zeitzmann, I Chalamon, RE Wokutch, P Thakur
Journal of Business Ethics 117 (1), 45-65, 2013
302013
Run away or stick together? The impact of organization-specific adverse events on alliance partner defection
O Bruyaka, D Philippe, X Casta˝er
Academy of Management Review 43 (3), 445-469, 2018
242018
Impact of HIPAA provisions on the stock market value of healthcare institutions, and information security and other information technology firms
L Khansa, DF Cook, T James, O Bruyaka
computers & security 31 (6), 750-770, 2012
202012
Flow signals: Evidence from patent and alliance portfolios in the US biopharmaceutical industry
T Caner, O Bruyaka, JE Prescott
Journal of Management Studies 55 (2), 232-264, 2018
192018
Better at home, abroad, or both? How Chinese firms use ambidextrous internationalization strategies to drive innovation
C Prange, O Bruyaka, R Tung, GK Stahl
Cross Cultural & Strategic Management, 2016
192016
Using network-based text analysis to analyze trends in Microsoft's security innovations
TL James, L Khansa, DF Cook, O Bruyaka, KB Keeling
computers & security 36, 49-67, 2013
92013
ALLIANCE PARTNER DIVERSITY AND BIOTECH FIRMS'EXIT: DIFFERING EFFECTS ON DISSOLUION VS. DIVESTMENT.
OP BRUYAKA
Academy of management proceedings 2008 (1), 1-6, 2008
82008
Investigating the transformation and transition processes between dynamic capabilities: evidence from DHL
C Prange, O Bruyaka, K Marmenout
Organization Studies 39 (11), 1547-1573, 2018
62018
Co-evolutionary perspective on sourcing portfolios: Examining sourcing choices for clinical trials of bio-pharmaceutical firms
P Thakur-Wernz, O Bruyaka
Management International Review 57 (6), 909-946, 2017
42017
Performance de la RD
O Bruyaka
Revue franšaise de gestion, 23-36, 2005
42005
Reexamining CEO duality: The surprisingly problematic issues of conceptualization and measurement
S Gove, M Junkunc, O Bruyaka, LR Kabbach de Castro, ...
Corporate Governance: An International Review 25 (6), 411-427, 2017
32017
Strategic complementarities in M&As: evidence from the US information retrieval services industry
O Bruyaka, T James, DF Cook, R Barkhi
Information Technology and Management 16 (2), 97-116, 2015
22015
Antecedents and relative performance of sourcing choices for new product development projects
P Thakur-Wernz, O Bruyaka, F Contractor
Technovation 90, 102097, 2020
12020
Tapping Regional And Corporate Scientific Knowledge For Innovation: The Moderating Role Of Scientific Knowledge Duration
O Bruyaka, FX Ji, LF Tegarden, DE Hatfield, WB Lamb
International Journal of Innovation Management 19 (01), 1550001, 2015
12015
Patent and alliance portfolio flow signals: Evidence from the US biopharmaceutical industry
T Caner, O Bruyaka, JE Prescott
Academy of Management Proceedings 2015 (1), 10099, 2015
12015
Overcoming innovation barriers: Alliance portfolio characteristics and technological innovations
MK Srivastava, O Bruyaka, DR Gnyawali
12013
Run Away or Stick Together? Predicting Alliance Termination in Light of Adverse Events
OP Bruyaka, D Philippe
Academy of Management Proceedings 2012 (1), 12713, 2012
12012
Alliance portfolio diversity and market scope: direct and interaction effects on biotech firms' exit
O Bruyaka
HAL Post-Print, 2008
12008
The system can't perform the operation now. Try again later.
Articles 1–20